VEA
KYTX icon

Virtus ETF Advisers’s Kyverna Therapeutics KYTX Stock Holding History

Virtus ETF Advisers’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-6,381
Closed -$31.2K – 506
2024
Q3 		$31.2K Buy
6,381
+112
+2% +$863 0.01% 450
2024
Q2 		$47K Buy
+6,269
New +$95.8K 0.02% 445

Other funds holding KYTX

VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Virtus ETF Advisers's KYTX Position: Q4 2024 in Review

Virtus ETF Advisers sold out of Kyverna Therapeutics (KYTX) in Q4 2024, closing a stake of 6,381 shares — an estimated $31.2K sold.

Virtus ETF Advisers first reported a position in KYTX in Q2 2024 and held it in 2 quarters. The position peaked at $47K in Q2 2024. 88 funds tracked by Wall St. Rank hold KYTX as of Q4 2024.

  • Virtus ETF Advisers reported no remaining Kyverna Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Virtus ETF Advisers sold 6,381 Kyverna Therapeutics shares in Q4 2024, an estimated $31.2K.
  • Virtus ETF Advisers first reported a position in Kyverna Therapeutics in Q2 2024 and held it in 2 quarters.
  • Virtus ETF Advisers's Kyverna Therapeutics position peaked at $47K in Q2 2024.
  • 88 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q4 2024.

Based on Virtus ETF Advisers's 13F filing for Q4 2024, filed 14 Feb 2025.